Quarterly report pursuant to Section 13 or 15(d)

Note 2 - Significant Accounting Policies and Basis of Presentation (Details Textual)

v3.10.0.1
Note 2 - Significant Accounting Policies and Basis of Presentation (Details Textual) - USD ($)
shares in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Cost Reimbursements from SBIR Grant as Offset to Research and Development Expenses $ 143,000 $ 0 $ 318,000 $ 0
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9.7 10.0 9.7 9.2
Asset Impairment Charges, Total $ 0 $ 0 $ 0 $ 0